Why Aprepitant Struggles to Be Absorbed, and How New Formulations Are Fixing It

Nanotechnology, self-microemulsifying systems, sustained release and new delivery routes are reshaping how nausea and vomiting are controlled during chemotherapy.

In brief: Aprepitant is a cornerstone antiemetic for chemotherapy-induced nausea and vomiting (CINV), but its poor solubility limits how well the body absorbs it. New formulation technologies are designed to solve that problem.

Why CINV still matters

Cancer therapies have improved outcomes, but nausea and vomiting remain among the most disruptive side effects. They can affect eating, sleep and daily life, and for some patients they lead to stopping chemotherapy altogether.

Neurokinin-1 (NK-1) receptor antagonists are now core antiemetics for moderate- to high-emetogenic-risk regimens. Aprepitant blocks substance P from binding to NK-1 receptors. This makes it especially important for controlling delayed nausea and vomiting, and a key part of first-line antiemetic therapy.

The absorption problem

Aprepitant is often classed as a BCS Class IV drug, meaning low solubility and low permeability. Its aqueous solubility is only about 3–7 μg/mL across pH 2–10, which limits absorption after oral dosing.

Traditional formulations face several practical limits:

• Low water solubility → limited bioavailability
• Strong food effects → variable efficacy
• Hepatic first-pass metabolism → less drug actually absorbed
• Oral dosing during severe vomiting → hard for patients to take
• Intravenous formulations → require infusion, which limits long-term adherence

From "does it work?" to "is it delivered well?"

Antiemetic development used to ask mainly whether a drug was effective. Now the questions are broader:

• Is absorption consistent?
• Is onset fast?
• Can the duration of action be extended?
• Does the long-term patient experience improve?

The main research directions are nanotechnology-based formulations, solid dispersions, self-microemulsifying drug delivery systems (SMEDDS) and long-acting sustained-release technologies. All of them aim to improve aprepitant's solubility and bioavailability.

Nanotechnology: smaller particles, better absorption

Shrinking drug particles to the nanoscale greatly increases their surface area, which improves dissolution and absorption. Compared with conventional formulations, this can mean:

• Faster dissolution
• Better gastrointestinal absorption
• Improved bioavailability
• Smaller swings in plasma concentration

Studies suggest nano-formulated aprepitant reaches systemic circulation faster and may be less affected by food. Nanocrystals, polymeric nanoparticles and lipid-based nanocarriers are all under active development.

SMEDDS: a strong fit for a lipophilic drug

Aprepitant is highly lipophilic, so self-microemulsifying drug delivery systems have drawn considerable interest. These systems form tiny emulsion droplets in the gut, improving dispersion and dissolution. They can also make absorption more stable and reduce variability between patients.

At DengYueMed, we believe this approach could extend well beyond aprepitant to many other poorly soluble anticancer drugs.

Sustained release: fewer peaks and troughs

Conventional aprepitant is effective, but plasma levels can fluctuate and dosing can be frequent. Sustained-release and long-acting systems control how quickly the drug is released. This prolongs its action, keeps plasma levels steadier and may reduce the overall treatment burden. For patients facing multiple chemotherapy cycles, that matters.

New routes of administration

Researchers are also exploring intranasal, transdermal and buccal mucosal delivery. These routes bypass the gastrointestinal tract, which could be especially valuable for patients who cannot keep oral medication down. In the future, multi-route strategies may become part of more precise CINV management.

What comes next

Antiemetic therapy affects not only patient comfort but also how well anticancer treatment can be delivered. Future progress in CINV will depend on more than the drug itself:

• Delivery efficiency
• Long-acting capability
• Speed of onset
• Convenience of administration
• Patient adherence

Conclusion

Aprepitant has proven clinical value in controlling delayed nausea and vomiting, but its low solubility has long held back its full potential. Advances in nanotechnology, SMEDDS and sustained-release platforms are moving it from a "poorly soluble drug" toward a new generation of high-absorption therapies. As these technologies mature, CINV care is expected to become more precise, longer-acting and more individualized.

Follow DengYueMed for more updates on medical and drug-development news.